GlassScriptPhysician profile
Sara Marie Diskin
NPI 1023464369
$2,737.25
in general payments reported to CMS, 2019-2025
25 companies · $342 in 2025
The $342 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.36 · 2020: $182 · 2021: $241 · 2022: $607 · 2023: $696 · 2024: $603 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $665.32 | 2021-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $395.29 | 2020-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Ironshore Pharmaceuticals INC. | $337.96 | 2020-2024 | Jornay Pm |
| Kaleo, INC. | $233.72 | 2019-2023 | Auvi-Q |
| Glaxosmithkline, LLC. | $161.84 | 2021-2024 | Bexsero |
| Supernus Pharmaceuticals, INC. | $131.22 | 2023-2025 | Qelbree, Qelbree |
| Alexion Pharmaceuticals, INC. | $107.75 | 2024 | Koselugo |
| Takeda Pharmaceuticals U.S.A., INC. | $102.88 | 2020-2021 | |
| Sanofi Pasteur INC. | $62.43 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $61.63 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $56.41 | 2019-2023 | Cotempla Xr-Odt |
| Tempus Ai, INC | $51.95 | 2024 | |
| Noven Therapeutics, LLC | $50.10 | 2023 | Xelstrym |
| Tris Pharma INC | $50.02 | 2019-2025 | Dyanavel Xr |
| Cranial Technologies, INC | $34.34 | 2023-2025 | Doc Band |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $30.98 | 2025 | Immunocap |
| Sanofi-Aventis U.S. LLC | $30.64 | 2025 | |
| Pfizer INC. | $29.47 | 2019-2024 | |
| Neurelis, INC. | $25.10 | 2022 | |
| Verrica Pharmaceuticals INC. | $24.79 | 2023 | Ycanth |
| Biomarin Pharmaceutical INC. | $22.50 | 2024 | Voxzogo 1.2mg |
| Ultragenyx Pharmaceutical INC. | $19.85 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $19.76 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.84 | 2025 | Zoryve |
| Vertical Pharmaceuticals, LLC | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Diskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.